Latest Share Chat

EVG.L Share News (EVG)

EVG.L Information

There is currently no data for EVG

Tueday broker round-up

Tue, 11th Sep 2018 12:51

(Sharecast News) - JD Wetherspoons: Berenberg upgrades to buy with a target price of 1,450p.BP: Berenberg reiterates buy with a target price of 665p.Royal Dutch Shell B: Berenberg reiterates hold with a target price of 2,800p.BHP: Deutsche Bank downgrades to hold with a target price of 1,800p.South32: Deutsche Bank upgrades to buy with a target price of 235p.Associated British Foods: Kepler Cheuvreux reiterates buy with a target price of 2,600p.Ted Baker: Liberum reiterates buy with a target price of 3,300p.Ashtead: Liberum reiterates buy with a target price of 2,650p.Helical Bar: Numis upgrades to buy with a target price of 432p.Elementis: Numis reiterates buy with a target price of 340p.Midwich: Canaccord reiterates hold with a target price of 707p.Evgen Pharma: Northland Capital Markets reiterates buy with a target price of 113p.Greene King: Berenberg reiterates sell with a target price of 430p.McBride: Berenberg reiterates hold with a target price of 140p.Team17: Berenberg reiterates buy with a target price of 290p.Gamma Communications: Barclays reiterates overweight with a target price of 1,000p.Whitbread: Barclays reiterates equal weight with a target price of 5,100p.

More News

8 Jun 2020 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

13 Feb 2020 16:17

Evgen Pharma, Rochester University To Advance SFX-01 For Trial

6 Feb 2020 13:45

Evgen Pharma Hails "Positive" Data From Breast Cancer Drug Research

17 Dec 2019 15:35

Evgen Pharma narrows loss, foresees 'clinical success'

(Sharecast News) - Evgen Pharma on Tuesday reported a narrowed interim loss and said it was confident of clinical success as it continues to develop its SFX-01 treatment.

17 Dec 2019 11:28

Evgen Pharma Outlook Confident Amid Clinical Success And Trimmed Loss

10 Dec 2019 15:59

UK Earnings, Trading Statements Calendar - Next 7 Days

5 Dec 2019 16:36

Evgen Pharma to advance SFX-01 trial with University of Dundee

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has entered into a memorandum of understanding with the University of Dundee, it announced on Thursday, to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis (NASH) and liver fibrosis.

5 Dec 2019 15:19

Evgen Pharma, University Of Dundee To Collaborate To Advance SFX-01 Trials

11 Nov 2019 12:23

UPDATE: Evgen Pharma "Unlikely" To Pursue Subarachnoid Development

11 Nov 2019 10:22

UK WINNERS & LOSERS SUMMARY: Greggs Surges 17% After Raising Guidance

11 Nov 2019 09:11

Evgen Pharma Shares Drop On "Disappointing" SFX-01 Trial Results

23 Sep 2019 13:09

Evgen Pharma "Delighted" With Extended Breast Cancer Treatment Results

23 Sep 2019 10:03

Evgen Pharma upbeat on latest news from SFX-01 studies

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Monday that five patients who participated in the 'STEM' trial received 'SFX-01' treatment for more than one year, with two of those patients continuing to be treated with SFX-01.

28 Aug 2019 14:30

Evgen Pharma completes patient study visits in 'SAS' phase 2 trial

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that the last study visit for the last patient entered in the double-blind, placebo-controlled 'SAS' phase 2 clinical trial has taken place.

28 Aug 2019 12:06

Evgen Pharma Receives Last Patient For Stroke Treatment Drug Trial

(Alliance News) - Evgen Pharma PLC said Wednesday it has entered its last patient in the double-blind, placebo-controlled SAS Phase II clinical trial that is testing its SFX-01 product, aimed at a

Latest Share Chat

EVG.L Share News (EVG)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tueday broker round-up

Login to your account

Quickpicks are a member only feature

Login to your account